Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT03251118
Active, not recruiting Observational

A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease

NCT03251118 · tracked via the Priya Life Science USA tracker
Sponsor
Target PharmaSolutions, Inc
Phase
Observational
Started
2017-07-24
Last updated
2026-03-17

Condition(s) studied

Inflammatory Bowel DiseasesCrohn's DiseaseUlcerative ColitisIndeterminate Colitis

Study summary

TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical practice. TARGET-IBD will create a research registry of patients with IBD within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.

Eligibility

Sex
ALL
Min age
2 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Adults and children (age 2 or older) with a diagnosis of Crohn's disease (CD), Ulcerative colitis (UC), or Indeterminate colitis (IBDU) having been prescribed any IBD treatment (initial or subsequent) outside of a clinical trial. 2. Have plans for future visits at the site for continued management of IBD. Exclusion Criteria: 1. Inability to provide written informed consent/assent. 2. Being enrolled in any interventional study or trial for IBD treatment. Note: Patient may be enrolled in other registries or studies where IBD treatment outcomes are observed and/or reported (such as center-based registries). 3. Prior total abdominal colectomy for UC or IBDU.

Primary outcome measure(s)

  • Natural history of Inflammatory Bowel Disease: Characteristics of IBD — Up to 5 years
  • Natural history of Inflammatory Bowel Disease: Participant demographics — Up to 5 years
  • Natural history of Inflammatory Bowel Disease: Treatment use — Up to 5 years
  • Natural history of Inflammatory Bowel Disease: Treatment response — Up to 5 years
  • Natural history of Inflammatory Bowel Disease: Disease progression — Up to 5 years

Trial sites (37)

FacilityCityRegionStatus
Om Research Lancaster California
FACEY Medical Foundation Mission Hills California
University of California - Davis Sacramento California
Stanford University Stanford California
University of Colorado Denver Aurora Colorado
Gastro Florida Clearwater Florida
University of Florida Health Jacksonville-Gastroenterology Jacksonville Florida
Advanced Gastroenterology Associates, LLC Palm Harbor Florida
Atlanta Gastro Atlanta Georgia
The University of Chicago Medical Center Chicago Illinois
Indianapolis Gastroenterology Research Foundation Indianapolis Indiana
University of Iowa Hospitals and Clinics Iowa City Iowa
Gastroenterology Associates Baton Rouge Louisiana
Louisiana Research Center, LLC Shreveport Louisiana
University of Michigan Medical Center Ann Arbor Michigan
University of Minnesota Minneapolis Minnesota
Saint Louis University St Louis Missouri
University of Nebraska Medical Center Omaha Nebraska
Dartmouth-Hitchcock Medical Center Lebanon New Hampshire
Rutgers, Robert Wood Johnson Medical School New Brunswick New Jersey
NYU Langone Health New York New York
Mount Sinai, Icahn School of Medicine New York New York
Premier Medical Group of the Hudson Valley Poughkeepsie New York
The Children's Hospital at Montefiore The Bronx New York
Cary Gastroenterology Associates Cary North Carolina
University of North Carolina Chapel Hill North Carolina
Carolinas Healthcare System-Center for Digestive Health Charlotte North Carolina
Digestive Health Specialists, PA Winston-Salem North Carolina
Cleveland Clinic/DIgestive Disease and Surgery Institute Cleveland Ohio
The Ohio State University Wexner Medical Center Columbus Ohio
University of Pennsylvania Philadelphia Pennsylvania
Vanderbilt University Medical Center Nashville Tennessee
UT Southwestern Dallas Texas
Baylor College of Medicine Houston Texas
Swedish Medical Center Seattle Washington
MultiCare Institute for Research and Innovation Tacoma Washington
University of Wisconsin Hospital & Clinics Madison Wisconsin

More Target PharmaSolutions, Inc. trials in the USA

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC Active, not recruiting
An Observational Study of Patients With Dermatologic Disease Starting soon
An Observational Study of Patients With Chronic Liver Disease Enrolling by invitation
A Longitudinal Observational Study of the Natural History and Management of Patients With HCC Active, not recruiting
An Observational Study of Patients With Chronic Gastrointestinal Disease Active, not recruiting

Other trials for the same condition

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease Active, not recruiting
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis Active, not recruiting
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis Recruiting
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis Active, not recruiting
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03251118 on ClinicalTrials.gov ↗ ← All trials in the USA